|
Variable
|
BPO without OAB (n = 892)
|
BPO with coexisting OAB (n = 584)
|
P value
|
|---|
|
Prostate volume (mL)
|
55.6 ± 20.7
|
62.7 ± 26.5
|
0.005
|
|
Serum PSA (ng/mL)
|
3.6 ± 0.8
|
3.7 ± 0.7
|
0.624
|
|
Testosterone (nmol/L)
|
14.2 ± 4.6
|
13.9 ± 4.3
|
0.196
|
|
Qmax (mL/s)
|
10.2 ± 3.9
|
10.1 ± 3.8
|
0.162
|
|
PVR (mL)
|
19.8 ± 17.3
|
20.5 ± 18.7
|
0.820
|
|
BMI (kg/m2)
|
24.3 ± 3.7
|
24.6 ± 4.1
|
0.461
|
|
IPSS (score)
|
19.2 ± 6.8
|
23.5 ± 7.3
|
0.000
|
|
QoL (score)
|
3.9 ± 0.9
|
4.6 ± 1.2
|
0.000
|
|
IIEF-5 (score)
|
9.9 ± 2.3
|
9.0 ± 1.7
|
0.036
|
- BPO Benign prostatic obstruction, OAB Overactive bladder syndrome, PSA Prostate-specific antigen, Qmax Maximum flow rate, PVR Postvoid residual urine volume, IPSS International prostate symptom score, QoL Quality of life, IIEF-5 International index of erectile function-5, OABSS Overactive bladder symptom score
